Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
49
resultados
Última actualización
07/08/2025 [06:45:00]
Resumen de: AU2025205481A1
The present invention relates to administration speed of obinutuzumab. The present invention relates to administration speed of obinutuzumab. ul u l h e p r e s e n t i n v e n t i o n r e l a t e s t o a d m i n i s t r a t i o n s p e e d o f o b i n u t u z u m a b
Resumen de: WO2024068960A1
The present invention relates to the method for producing a three-dimensional (3D) model of multiple myeloma (MM), in the form of spheroids, by co-culturing stem cells/mesenchymal stromal cells, endothelial progenitors and primary plasma cells of one or more MM patients. The present invention also relates to the spheroids obtained by said method, and uses thereof.
Resumen de: EP4596535A1
The present disclosure provides a proteolysis-targeting compound TPB-L-E3B, a method for synthesizing the same, and use thereof. The compound can treat human tumor diseases through the eRF3a-targeting proteolysis mechanism, and exhibits great potential in treating such diseases in in-vitro studies, particularly, in treating diseases such as prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer, and the like.
Resumen de: MX2025002161A
The invention provides pyrazolylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condition, such as a proliferative disorder, inflammatory disorder, or autoimmune disorder.
Resumen de: MX2025002784A
Compounds and pharmaceutical compositions comprising compounds that inhibit ENL/AF9 YEATS and FLT3 are disclosed herein. Methods for suppressing oncogene expression in a cell, or for treating acute leukemias, using the compounds and pharmaceutical compositions comprising the compounds are also disclosed. The compounds, pharmaceutical compositions and methods can be used to inhibit key drivers of cancer and cancer stem cell survival.
Resumen de: US2025243184A1
Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.
Resumen de: AU2025205394A1
Abstract Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods. Abstract Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods. ul b s t r a c t r o v i d e d a r e a d o p t i v e c e l l t h e r a p y m e t h o d s i n v o l v i n g t h e a d m i n i s t r a t i o n o f d o s e s o f c e l l s u l f o r t r e a t i n g d i s e a s e a n d c o n d i t i o n s , i n c l u d i n g c e r t a i n c e l l m a l i g n a n c i e s h e c e l l s g e n e r a l l y e x p r e s s r e c o m b i n a n
Resumen de: US2025236600A1
The present invention is comprised in the field of medicinal chemistry, and it is related to substituted vinyl piperazine-piperidine urea compound which are well effective as antitumoral agents. In particular, they are suitable in methods of treatment of glioblastoma (GB), multiple myeloma (MM) or pancreatic cancer (PC).
Resumen de: US2025236621A1
The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
Resumen de: AU2025205154A1
CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4- phenoxyphenyl)-1H-pyrazolo3,4-dpyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk in hibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-(R)-3-(4-amino-3-(4- phenoxyphenyl)-1H-pyrazolo3,4-dpyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one,1 including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk in hibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. ul ' u l e s c r i b e d h e r e i n i s t h e r u t o n ' s t y r o s i n e k i n a s e ( t k ) i n h i b i t o r - ( ) - - ( - a m i n o - - ( - p h e n o x y p h e n y l ) - - p y r a z o l
Resumen de: AU2023390460A1
The present disclosure provides methods of administering belumosudil to patients with multiple myeloma.
Resumen de: US2025236607A1
Described herein are CDK9 degraders that include a CDK9 binding moiety, such as AT7519 or VIP152, conjugated to a E3 ubiquitin ligase binding moiety, such as thalidomide, lenalidomide, or pomalidomide. These degraders can induce the ubiquitination of CDK9 and promote its degradation in cells. The linker covalently tethering the CDK9 binding moiety to the E3 ubiquitin ligase binding moiety can be selected to tune the solubility profile and potency of the degrader. Accordingly, the present disclosure provides compounds, compositions, kits, uses, and methods for the treatment of cancer (e.g., blood cancers such as acute myeloid leukemia or acute lymphoblastic leukemia).
Resumen de: US2025235465A1
Methods and corresponding uses are provided for treating disease in a patient, involving the use of sodium trans-tetrachloridobis(1H-indazole)ruthenate(III) so as to ameliorate drug resistance, including resistance to proteasome inhibitors and immunomodulatory imide drugs. The disease may for example be relapsing/refractory multiple myeloma.
Resumen de: US2025235454A1
A compound derived from an aliphatic diamine including at least one pyridine or pyrimidine unit, for use as an anticancer agent, to a therapeutic composition including this compound, to a product including such a compound and another active agent, as well as to such a compound.
Resumen de: US2025236889A1
The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARS, recognition domains, and/or pH-modulating agents.
Resumen de: US2025235535A1
The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that binds to CD64, and methods of use in treating acute myeloid leukemia.
Resumen de: US2025236642A1
As a technique that can be used for cancer immunotherapy of adult T-cell leukemia (ATL), provided is a pharmaceutical composition for treatment or prevention of adult T-cell leukemia, the pharmaceutical composition containing a peptide consisting of an amino acid sequence of any one of SEQ ID NOs: 1 to 68.
Resumen de: AU2024228130A1
The present invention relates to a nucleic acid encoding a recombinase capable of recombining asymmetric target sequences of SEQ ID NO:1 within the long terminal repeat of proviral DNA of a plurality of HTLV-1 strains, the recombinase having specific amino acid exchanges compared to the sequence of cre recombinase. The invention also provides expression vectors comprising said nucleic acids and cells comprising the same, the recombinase in protein form and pharmaceutical compositions comprising them. A method for provision of such recombinases is also provided. The invention also provides a method of treating a HTLV-1-infected subject, wherein the subject optionally has adult T-cell leukemia (ATL) and/or HTLV-1-associated myelopathy (HAM).
Resumen de: AU2024208091A1
This application pertains to the use of compounds, e.g., Compound A: or a pharmaceutically acceptable salt thereof, for the treatment of various diseases or disorders, including, for example, diffuse large B-cell lymphoma (DLBCL) and angioimmunoblastic T- cell lymphoma.
Resumen de: WO2025155777A1
Disclosed herein are novel compounds that are Mpsl/TTK inhibitors. Also disclosed are compositions comprising the compounds and methods of using the compounds in treating various diseases. In some embodiments, some such compounds, compositions, and their uses may be useful for the treatment of cancer. In some implementations, the cancer is brain cancer, glioblastoma multiforme, head and neck cancers, colorectal cancer, stomach or gastric cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, renal cell carcinoma, breast cancer, ovarian cancer, lymphoma, thyroid cancer, mesothelioma, sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer, or endometrial cancer.
Resumen de: WO2025155780A1
Disclosed herein are novel compounds that are Mpsl/TTK inhibitors. Also disclosed herein are compositions comprising the compounds and methods of using the compounds in treating various diseases in a patient. In some embodiments, some such compounds, compositions, and their uses may be useful for the treatment of cancer. In some implementations, the cancer is brain cancer, glioblastoma multiforme, head and neck cancers, colorectal cancer, stomach or gastric cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, renal cell carcinoma, breast cancer, ovarian cancer, lymphoma, thyroid cancer, mesothelioma, sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer, or endometrial cancer.
Resumen de: WO2025153509A1
A first aspect of the invention relates to a variant prime editing polypeptide composed of a SpCas9 nickase fused to an engineered Moloney Murine leukaemia virus (M-MLV) reverse transcriptase, characterized by a mutation, relative to a reference sequence SEQ ID NO 001, selected from the group consisting of A277D; K1865T; and S237A. Another aspect of the invention relates to a combination of a first and second split PE variant polypeptide comprising split intein component at its C- and N-terminus, respectively, which, when both are present within a target cell, are capable of forming a fusion polypeptide comprising a functional prime editing polypeptide according to the first aspect of the invention. Other aspects of the invention relate to a combination medicaments and nucleic acid sequences facilitating the PE variant of the invention.
Resumen de: WO2025155775A1
Methods of detecting leukemia stem cells are provided herein. Further provided are methods of diagnosing and treating AML as well as minimal residual disease or medium- or high-risk AML.
Resumen de: EP4588492A2
Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radio-therapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.
Resumen de: EP4588484A2
The present disclosure provides methods for treating multiple myeloma (such as refractory multiple myeloma or relapsed and refractory multiple myeloma) in an individual who received at least two prior therapies for multiple myeloma. The methods comprise administering to the individual an anti-CD38 antibody, pomalidomide, and dexamethasone. Also provided are methods of improving renal impairment in an individual having multiple myeloma.
Resumen de: US2025230202A1
The present disclosure provides use of a promyelocytic leukemia 1 (PML-1) protein in preparation of a drug for inhibiting a cytokine storm, and belongs to the technical field of biomedicine. The present disclosure further provides use of a PML-1 protein and/or a product expressing the PML-1 protein in preparation of a drug for inhibiting a cytokine storm. In the present disclosure, the PML-1 protein and/or the product expressing the PML-1 protein can significantly inhibit the expression of proteins TAB1, TAK1, and p-TAK1 and inhibit inflammatory cytokines TNF-α, IL-1β, MIP-1α, IL-6, IL-8, and MCP-1 in an inflammatory signaling pathway, thereby inhibiting the cytokine storm. The PML-1 protein can be directly used for the treatment of inflammations and related diseases. Compared with traditional chemical anti-inflammatory drugs, the protein shows more significant curative effect, stronger specificity, lower toxicity, smaller side effects, and clearer biological functions, exhibiting broad application prospects.
Resumen de: US2025228918A1
Described herein are a method of increasing energy expenditure level in a subject, a method of reducing body weight in a subject, a method of decreasing the amount of white adipose (WAT) tissue and/or promoting browning of WAT in a subject, and/or a method of improving glucose tolerance and/or insulin sensitivity in a subject. Each of the methods includes downregulating the level and/or activity of Augmentor α (Augα), or downregulating the level and/or activity of anaplastic lymphoma kinase (ALK) in the subject. Also described herein are a method of decreasing energy expenditure level in a subject, and/or a method of increasing body weight in a subject. Each of the methods includes upregulating the level and/or activity of Augα, or upregulating the level and/or activity of ALK in the subject.
Resumen de: US2025231193A1
T-cell malignancies are a broad, heterogenous group of diseases and include T-cell lymphomas and T-cell leukemias. T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sézary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors showed that both circulating malignant and non-malignant T cells express CD51 in patients with Sézary syndrome. CD51 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas.
Resumen de: US2025230252A1
Methods of treating acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) are provided, as are compositions and combinations suitable for use in said methods.
Resumen de: US2025228881A1
A novel multi-fused-ring compound and a composition for preventing or treating multiple myeloma comprising the same as an active ingredient is described herein. The compound is a derivative synthesized from the natural compound ginsenoside as a starting material, and shows no cytotoxicity to normal hematopoietic stem cells, while exhibiting a significant killing effect on various multiple myeloma cell lines, indicating that it may be administered for a long period of time without side effects. In addition, the compound exhibits a significant synergistic effect when co-administered with the immunomodulator thalidomide or its analog lenalidomide, and thus may be useful as an efficient therapeutic agent or therapeutic aid agent composition for multiple myeloma, an incurable disease.
Resumen de: US2025228783A1
Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo 3,4-dpyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Resumen de: US2025230234A1
The present disclosure provides antigen-binding proteins specifically binding GPRC5D, as well as respective antibodies in enhanced ADCC formats, and methods of using them to treat cancers such as multiple myeloma.
Resumen de: EP4585273A2
The present disclosure provides combination therapy comprising a BET inhibitor and a protein phosphatase 2A (PP2A) activator, a B-cell lymphoma-2 (Bcl-2) inhibitor, a B-cell lymphoma-extra large (Bcl-xl) inhibitor, a casein kinase 2 (CK2) inhibitor, and/or a mediator complex subunit 1 (MED1) for cancer. The combination therapy is expected to be synergistic in treating the cancer, compared to the monotherapy. Methods for identifying a subject having a cancer that is resistant to or at risk of developing resistance to bromodomain and extra terminal (BET) inhibitor therapy are also provided.
Resumen de: EP4585253A2
A method of enhancing embryo implantation in a subject is disclosed which comprises administering to the uterine cavity of the subject a formulation comprising copper and/or zinc in an amount effective to stimulate endometrial production of leukaemia inhibitory factor (LIF) and/or vascular endothelial growth factor (VEGF). Alternatively, a device may be inserted into the uterine cavity of the subject, wherein the device comprises copper and/or zinc, for a period of time that is effective to stimulate endometrial production of LIF and/or VEGF. The method is suitable for use with women undergoing treatment by any of the assisted reproductive technologies, such as those involving the transfer of embryos such as in vitro fertilisation (IVF) and variants including IVF-ICSI (intracytoplasmic sperm injection) and in vitro maturation (IVM) treatments, as well as intrauterine-insemination (IUI) therapy. However, the method is also applicable for women wanting to improve their prospects of pregnancy through natural conception.
Resumen de: KR20250107512A
본 발명은 다중 광원을 이용한 림프부종 진단을 위한 촬영장치에 관한 것으로, 보다 상세하게는, ICG(인도시아닌그린, Indocyanine green)가 주입된 피검자의 신체를 촬영하는 카메라부, 상기 신체에 다중광원을 조사하는 다중광원부 및, 상기 카메라부 및 다중광원부가 수용되도록 하는 하우징부를 포함하고, 상기 다중광원부는, 700nm 내지 800nm 파장의 광원과 800nm 내지 820nm 파장의 광원이 상기 신체에 조사될 수 있도록 하는 것을 특징으로 한다. 또한, 본 발명에 따르면, 한 대의 카메라로 700nm 파장대 및 800nm 파장대의 광원이 조사된 신체의 이미지가 촬영되도록 하여 림프부종 진단용 이미지가 획득될 수 있도록 하는 효과가 있다.
Resumen de: US2025223360A1
The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
Resumen de: US2025221961A1
The disclosure herein provides combination therapies for the treatment of cancers such as Leukemia, lymphoma and triple negative breast cancer. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by Formula I:or a pharmaceutically acceptable salt thereof together with a BCL-2 inhibitor or proteasome inhibitor for the treatment of cancer.
Resumen de: US2025221944A1
The present invention provides a novel compound having a chromanone or its ring-opening form, phenylpropenone, as backbone and compositions for the preventing or treating multiple myeloma, comprising the same. The compounds of the invention exhibit significant killing effects against various multiple myeloma cell lines and show in vivo anti-cancer effects that exceed those of lenalidomide, a commercially available immunomodulator widely used in the treatment of multiple myeloma and myelodysplastic syndromes. In addition, the compounds of the invention exhibit a significant synergistic effect when co-administered with the thalidomide or its analog lenalidomide, and thus are useful as an efficient therapeutic agent or therapeutic aid agent composition for multiple myeloma which is an incurable disease.
Resumen de: WO2025145476A1
Disclosed in the present invention is a use of an MP1 gene copy number variation detection reagent in preparation of an NK/T cell lymphoma prognosis kit. The present invention further provides a detection kit comprising the LMP1 gene copy number variation detection reagent, a use thereof, and an NK/T cell lymphoma prognosis method. In the present invention, a copy number variation event of LMP1 gene in an EB virus genome is used as a novel prognosis marker, which has a good prediction value for the overall survival and progression-free survival prognosis of an NK/T cell lymphoma patient, and can realize more accurate and effective prognostic assessment for the NK/T cell lymphoma patient.
Resumen de: WO2025145959A1
Disclosed in the present invention are three crystal forms of thienopyrimidine compound A and a preparation method therefor, wherein crystal form I is of a trihydrochloride salt, and crystal forms II and III are of dihydrochloride salts. The three crystal forms all have good stability and solubility, with a solubility of ≥4 mg/mL in a 5% aqueous glucose solution, so that the basic requirements for the solubility of a compound to be prepared into a lyophilized preparation for injection are met. The three crystal forms of thienopyrimidine compound A prepared in the present invention have good stability and solubility, can be prepared into a lyophilized preparation for clinical injection, and can be used for the effective treatment of patients with advanced, recurrent, etc. lymphoma, myeloma and lymphocytic leukemia, or drug-resistant patients.
Resumen de: WO2025147212A1
The invention relates to a kit for disrupting binding sites of repressor leukemia/lymphoma-related factor (LRF) of a promotor of a hemoglobin gamma (HbG) locus, compositions comprising said kit, and medical use thereof for treating and preventing β-hemoglobinopathy in a subject, wherein the kit comprising a CRISPR-Cas9 nickase and a pair of guide RNAs (gRNAs), wherein the pair of gRNAs binds to target sequences and results in a disruption of binding sites of repressor LRF in a promotor of HbG locus.
Resumen de: AU2023385514A1
The instant invention relates to combinations of an LSD1 inhibitor (or a pharmaceutically acceptable salt thereof) and a Menin inhibitor (or a pharmaceutically acceptable salt thereof). The combinations are particularly useful for treating cancer, including hematological cancers, such as acute myeloid leukemia or myelodysplastic syndrome.
Resumen de: US2025222107A1
The present disclosure provides chimeric antigen receptor (CAR) molecule specific for B cell maturation antigen (BC-MA), compositions and methods for treating immune-related disorders, specifically, plasma cell pathologies such as multiple myeloma (MM).
Resumen de: US2025223230A1
Introduction: Rituximab (R) is an integral component of therapy for B-cell lymphoid malignancies; bortezomib (Btz) has shown provocative single agent activity in Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL) and Waldenstrom's Macroglobulinaemia (WM), providing the rationale for investigating the combination.Patients+Methods: Forty-five adult patients (pts.) (30 men, 15 women) with histologically confirmed recurrent CD20+ve FL, MCL or WM, median age 60 years (range 45-79), FL: 17, MCL: 18, WM: 10, stage III/IV 40 (93%), bone marrow (BM) infiltration 32 (73%), elevated LDH 22 (49%), performance status ≥1 22 (49%), were enrolled in a randomised trial comparing 2 schedules of Brz+R: Arm A (twice weekly) Btz: 1.3 mg/m2 (on days 1, 4, 8, 11 of a 21-day cycle) and R: 375 mg/m2 (on day 1) for 8 cycles, or Arm B (weekly) Btz: 1.6 mg/m2 (on days 1, 8, 15, 22 of a 35-day cycle) and R: 375 mg/m2 (on days 1, 8, 15, 22 of cycles 1 and 4) for 6 cycles (23 arm A, 22 arm B). The median number of previous treatments was 2 (range 1-7). Seventeen pts. had received a R-containing regimen, with response lasting >6 months, and 8 high-dose treatment. Response was evaluated using the IWR criteria (Cheson et al, JCO 17:1244, 1999) and the updated response criteria from the 3rd International Workshop on WM (Treon et al, Blood 107:3442, 2006)Results: Ability to deliver the therapy, toxicity and efficacy were equivalent in both arms. The median number of cycles given in arm A was 4 and 5 in arm
Resumen de: US2025222068A1
The present invention relates to a composition for preventing or treating lupus or glomerulonephritis comprising a recombinant stabilized Galectin-9 protein. Specifically, the recombinant stabilized Galectin-9 protein of the present invention has been confirmed to exhibit safety in a systemic lupus erythematosus (SLE) animal model, reduce skin lesions, lymphadenopathy, and proteinuria caused by lupus, ameliorate lupus nephritis and glomerulonephritis, and decrease the concentration of anti-dsDNA antibodies in plasma. Accordingly, the recombinant stabilized Galectin-9 protein of the present invention can be effectively used as an active ingredient in a composition for preventing or treating lupus or glomerulonephritis.
Resumen de: KR20250106340A
용해성 골병변(osteolytic bone lesion)을 동반하는 다발성 골수종에서 FLT3L과 골 용해의 연관성을 확인하고, 다발성 골수종에서 골 용해 현상을 대상으로 분자적 기전을 탐구하여, 다발성 골수종 진단 또는 예후 예측을 위한 바이오마커 조성물과, 다발성 골수종 치료 또는 개선을 위한 약학적 조성물로 활용 가능한 기술이 개시된다. 본 발명은 FLT3L(Fms-like tyrosine kinase 3 ligand) 단백질 또는 이를 코딩하는 유전자를 포함하는 다발성 골수종(multiple myeloma, MM) 진단용 바이오마커 조성물과, STAT3(Signal transducer and activator of transcription 3) 인산화 억제제를 유효성분으로 포함하는 다발성 골수종(multiple myeloma, MM) 치료 또는 개선용 약학적 조성물을 제공한다.
Resumen de: EP4582096A1
The present invention relates to a composition for preventing or treating lupus or glomerulonephritis comprising a recombinant stabilized Galectin-9 protein. Specifically, the recombinant stabilized Galectin-9 protein of the present invention has been confirmed to exhibit safety in a systemic lupus erythematosus (SLE) animal model, reduce skin lesions, lymphadenopathy, and proteinuria caused by lupus, ameliorate lupus nephritis and glomerulonephritis, and decrease the concentration of anti-dsDNA antibodies in plasma. Accordingly, the recombinant stabilized Galectin-9 protein of the present invention can be effectively used as an active ingredient in a composition for preventing or treating lupus or glomerulonephritis.
Resumen de: EP4582087A1
A method for treating lymphoma is provided. A pharmaceutical composition for treatment of lymphoma, including BCV, a pharmaceutically acceptable salt thereof, or a solvate thereof is used. The lymphoma may be EBV-positive lymphoma. The lymphoma may be MYC-positive lymphoma. The pharmaceutical composition may be used in combination with a chemotherapeutic agent.
Nº publicación: EP4580635A1 09/07/2025
Solicitante:
TAIHO PHARMACEUTICAL CO LTD [JP]
Taiho Pharmaceutical Co., Ltd
Resumen de: AU2022476674A1
The present disclosure relates generally to methods of treating T-cell lymphomas with combination therapies.
BOPI
Sede Electrónica
